Literature DB >> 10970691

MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells.

G K Chen1, G E Durán, A Mangili, L Beketic-Oreskovic, B I Sikic.   

Abstract

Single-step selection with vinblastine was performed in populations of the human sarcoma cell line MES-SA, to assess cellular mechanisms of resistance to the drug and mutation rates via fluctuation analysis. At a stringent selection with 20 nM vinblastine, resulting in 5-6 logs of cell killing, the mutation rate was 7 x 10(-7)per cell generation. Analysis of variance supported the hypothesis of spontaneous mutations conferring vinblastine resistance, rather than induction of adaptive response elements. Surviving clones displayed a stable multidrug resistance phenotype over a 3-month period. All propagated clones demonstrated high levels of resistance to vinblastine and paclitaxel, and lower cross-resistance to doxorubicin and etoposide. Activation of MDR 1 gene expression and P-glycoprotein function was demonstrable in all clones. No elevation was found in the expression of the mrp gene, the LRP-56 major vault protein and beta-tubulin isotypes (M40, beta4, 5beta, and beta9) in these mutants. We conclude that initial-step resistant mechanism in these vinblastine-selected mutants commonly arises from a stochastic mutation event with activation of the MDR 1 gene. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10970691      PMCID: PMC2374671          DOI: 10.1054/bjoc.2000.1371

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

Review 1.  Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.

Authors:  C Dumontet; B I Sikic
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

Review 2.  Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.

Authors:  B I Sikic; G A Fisher; B L Lum; J Halsey; L Beketic-Oreskovic; G Chen
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

3.  Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbrück fluctuation analysis.

Authors:  T D Tlsty; B H Margolin; K Lum
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

4.  Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.

Authors:  P Giannakakou; D L Sackett; Y K Kang; Z Zhan; J T Buters; T Fojo; M S Poruchynsky
Journal:  J Biol Chem       Date:  1997-07-04       Impact factor: 5.157

Review 5.  Pitfalls and practice of Luria-Delbrück fluctuation analysis: a review.

Authors:  W S Kendal; P Frost
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

6.  Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).

Authors:  C Dumontet; G E Duran; K A Steger; L Beketic-Oreskovic; B I Sikic
Journal:  Cancer Res       Date:  1996-03-01       Impact factor: 12.701

7.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

8.  Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA.

Authors:  W G Harker; B I Sikic
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

Review 9.  Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly.

Authors:  F Cabral; S B Barlow
Journal:  FASEB J       Date:  1989-03       Impact factor: 5.191

10.  Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.

Authors:  L Beketic-Oreskovic; G E Durán; K G Chen; C Dumontet; B I Sikic
Journal:  J Natl Cancer Inst       Date:  1995-11-01       Impact factor: 13.506

View more
  14 in total

1.  Modulation of the anti-cancer efficacy of microtubule-targeting agents by cellular growth conditions.

Authors:  Jay F Dorsey; Melissa L Dowling; Mijin Kim; Ranh Voong; Lawrence J Solin; Gary D Kao
Journal:  Cancer Biol Ther       Date:  2010-05-15       Impact factor: 4.742

2.  Synthetic and Biological Studies of Sesquiterpene Polygodial: Activity of 9-Epipolygodial against Drug-Resistant Cancer Cells.

Authors:  Ramesh Dasari; Annelise De Carvalho; Derek C Medellin; Kelsey N Middleton; Frédéric Hague; Marie N M Volmar; Liliya V Frolova; Mateus F Rossato; Jorge J De La Chapa; Nicholas F Dybdal-Hargreaves; Akshita Pillai; Véronique Mathieu; Snezna Rogelj; Cara B Gonzales; João B Calixto; Antonio Evidente; Mathieu Gautier; Gnanasekar Munirathinam; Rainer Glass; Patricia Burth; Stephen C Pelly; Willem A L van Otterlo; Robert Kiss; Alexander Kornienko
Journal:  ChemMedChem       Date:  2015-10-05       Impact factor: 3.466

3.  Strategy for increasing drug solubility and efficacy through covalent attachment to polyvalent DNA-nanoparticle conjugates.

Authors:  Xue-Qing Zhang; Xiaoyang Xu; Robert Lam; David Giljohann; Dean Ho; Chad A Mirkin
Journal:  ACS Nano       Date:  2011-08-12       Impact factor: 15.881

4.  Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells.

Authors:  Alexander V Aksenov; Alexander N Smirnov; Igor V Magedov; Mary R Reisenauer; Nicolai A Aksenov; Inna V Aksenova; Alexander L Pendleton; Gina Nguyen; Robert K Johnston; Michael Rubin; Annelise De Carvalho; Robert Kiss; Véronique Mathieu; Florence Lefranc; Jaime Correa; David A Cavazos; Andrew J Brenner; Brad A Bryan; Snezna Rogelj; Alexander Kornienko; Liliya V Frolova
Journal:  J Med Chem       Date:  2015-02-20       Impact factor: 7.446

5.  Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins: Exploration of the N3 and N9 Positions and Interaction with Multidrug-Resistance Proteins.

Authors:  Ramesh Dasari; Andrzej Błauż; Derek C Medellin; Roaa M Kassim; Carlos Viera; Maximo Santarosa; Alet E van der Westhuyzen; Willem A L van Otterlo; Taryn Olivas; Tugba Yildiz; Tania Betancourt; Charles B Shuster; Snezna Rogelj; Błażej Rychlik; Todd Hudnall; Liliya V Frolova; Alexander Kornienko
Journal:  ChemMedChem       Date:  2019-01-25       Impact factor: 3.466

6.  Evolutionary approaches to prolong progression-free survival in breast cancer.

Authors:  Ariosto S Silva; Yoonseok Kam; Zayar P Khin; Susan E Minton; Robert J Gillies; Robert A Gatenby
Journal:  Cancer Res       Date:  2012-10-12       Impact factor: 12.701

Review 7.  Molecular pathways: regulation and therapeutic implications of multidrug resistance.

Authors:  Kevin G Chen; Branimir I Sikic
Journal:  Clin Cancer Res       Date:  2012-02-16       Impact factor: 12.531

Review 8.  Microtubule-binding agents: a dynamic field of cancer therapeutics.

Authors:  Charles Dumontet; Mary Ann Jordan
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

9.  Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?

Authors:  Fuxing Tang; Kazutoshi Horie; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

10.  Wittig derivatization of sesquiterpenoid polygodial leads to cytostatic agents with activity against drug resistant cancer cells and capable of pyrrolylation of primary amines.

Authors:  Ramesh Dasari; Annelise De Carvalho; Derek C Medellin; Kelsey N Middleton; Frédéric Hague; Marie N M Volmar; Liliya V Frolova; Mateus F Rossato; Jorge J De La Chapa; Nicholas F Dybdal-Hargreaves; Akshita Pillai; Roland E Kälin; Véronique Mathieu; Snezna Rogelj; Cara B Gonzales; João B Calixto; Antonio Evidente; Mathieu Gautier; Gnanasekar Munirathinam; Rainer Glass; Patricia Burth; Stephen C Pelly; Willem A L van Otterlo; Robert Kiss; Alexander Kornienko
Journal:  Eur J Med Chem       Date:  2015-08-29       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.